Alexion to expand Eculizumab sales with positive results from latest study
Boston-based biotech, Alexion, has stated that in a phase 3 study of the drug in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare CNS disease that can cause blindness, paralysis and death, Eculizumab secured its primary endpoint. Treatment with the drug reduced patients’ risk of relapse by 94.2% compared with placebo, and at the